Blockchain technology and crypto treasury strategies are revolutionizing funding for biomedical and scientific companies, paving the way for faster research and development of life-saving cures. Traditional capital formation and research funding structures are being overhauled to eliminate the delays that can hinder progress.
Portage Biotech, a leading biomedical technology company, made a strategic shift to become a Toncoin (TON) treasury company. By generating operating revenues through staking and investing in Telegram ecosystem projects, such as games and mini-apps, the company is able to fund cancer research and contribute to scientific advancements.
AlphaTON CEO Brittany Kaiser shared that the company plans to utilize the revenue from its operations and TON capital appreciation to support cancer research. In an interview with Cointelegraph, she mentioned exploring real-world asset tokenization as an innovative funding mechanism to democratize scientific development and eliminate financial barriers.
Differences between traditional scientific research funding models and decentralized science structures. Source: Cointelegraph
Kaiser and strategic advisor Anthony Scaramucci emphasized that AlphaTON’s focus on biomedical research sets it apart from other digital asset treasuries. The company aims to preserve the core aspects of its operating business while leveraging valuable assets within the organization.
Related: BNB treasury race accelerates as Applied DNA, CEA Industries expand holdings
Ideosphere’s Innovative Approach to Funding Scientific Research
Ideosphere, a decentralized science startup, is exploring the use of prediction markets to fund early-stage scientific research. By creating prediction market platforms that incentivize participation and idea exchange, the company aims to attract funding and support for research projects.
A mock-up example of the Ideosphere prediction market. Source: Ideosphere/Cointelegraph
Co-founder Rei Jarram highlighted the potential of prediction markets in creating a marketplace of ideas for researchers. By allowing traders to speculate on research hypotheses, Ideosphere aims to drive funding towards scientific innovation.
Bio Protocol’s Funding Milestone with Animoca Brands
Bio Protocol, a decentralized science platform leveraging AI, blockchain, and community engagement for drug discovery research, recently secured $6.9 million in funding from Animoca Brands and the Maelstrom fund. This investment is poised to transform the platform into an AI-native research market, revolutionizing scientific research practices.
Maelstrom founder Arthur Hayes expressed optimism about Bio Protocol’s potential to reshape the landscape of scientific research through innovative technologies and community collaboration.
Magazine: Crypto fans are obsessed with longevity and biohacking: Here’s why